cbdMD, Inc. Q1 2026 Earnings Call Summary

cbdMD, Inc. Q1 2026 Earnings Call Summary - Moby

Strategic Reset and Operational Recovery

Achieved three consecutive quarters of sequential revenue growth, which management views as a clear indicator that the core business is trending in the right direction. Performance was driven by improved execution in the core cbdMD brand and the wholesale channel, which grew 17% year-over-year. The company completed a deliberate multi-year reset focused on reducing fixed costs, simplifying operations, and strengthening the balance sheet for durable growth. Management attributed a 6% year-over-year gross margin decline to increased warehouse expenses and a shift in revenue mix toward the wholesale channel. The direct-to-consumer channel remains the primary revenue driver, representing approximately 72% of total revenue for the quarter. Regulatory challenges created packaging and compliance-related confusion among customers, though wholesale momentum remained encouraging despite this backdrop.

Integration Strategy and Regulatory Outlook

The second quarter focus is centered on integrating the Bluebird Botanicals acquisition, specifically consolidating supply chain, marketing, and operational areas to extract synergies. Management expects the Bluebird acquisition to provide a step-function increase in revenue at attractive contribution margins through a broader wellness portfolio. The company established a $20 million equity line of credit to opportunistically capitalize on potential positive stock movements while minimizing dilution. Guidance for the next quarter assumes a lower working capital build compared to the first quarter, excluding the specific impacts of the Bluebird acquisition. Strategic participation in Medicare-related CBD programs is underway ahead of an April pilot program, which management believes favors compliance-focused operators.

Capital Structure and Compliance Milestones

Regained full NYSE American continued listing compliance in early December, removing the company's previous temporary status. Completed a $2.25 million Series C preferred financing in December to strengthen liquidity and working capital positions. The acquisition of Bluebird Botanicals assets was structured with limited upfront equity and performance-based earn-outs to mitigate financial risk. Net loss per share improved significantly to $0.04 from $1.73 in the prior year, primarily due to the elimination of Series A preferred dividends.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Story Continues

Q&A Session Highlights

Integration and SKU rationalization strategy for Bluebird Botanicals

Management plans to maintain Bluebird and cbdMD as separate brands because they target slightly different customer bases. The company will look to bring certain cbdMD SKUs under the Bluebird label where it aligns with that specific customer profile to fill portfolio gaps.

Revenue contribution and growth trajectory of Oasis beverage brand

The beverage line is currently contributing to revenue but remains small relative to the core CBD brand. Management expects performance to improve throughout the year and will reassess specific disclosures as the brand gains more scale.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

View Comments